CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label → Bullish XBI
Question
CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label → Bullish XBI
Direct answer
Commercialization of gene-editing therapies is demonstrating accelerated inflection in real-world patient starts. CRISPR Therapeutics disclosed that quarterly Casgevy revenue climbed 78% sequentially to $76 million. The commercial ramp was supported by the FDA expanding Casgevy's approved indication to include pediatric patients aged 2 years and older, significantly expanding authorized treatment center throughput alongside partner Vertex Pharmaceuticals. — bullish pressure on XBI. — bullish pressure on XBI.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-09
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label → Bullish XBI”, revision 1, evidence through 2026-09-09. https://marketontology.com/catalysts/2026-09-09/crispr-therapeutics-casgevy-revenue-surges-78-qoq-to-76m-on-pediatric-label-bull-20c33f
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| XBI | ▲Bull | 1–4 weeks | Catalyst Driven | 65 |
CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label → Bullish XBI
Commercialization of gene-editing therapies is demonstrating accelerated inflection in real-world patient starts. CRISPR Therapeutics disclosed that quarterly Casgevy revenue climbed 78% sequentially to $76 million. The commercial ramp was supported by the FDA expanding Casgevy's approved indication to include pediatric patients aged 2 years and older, significantly expanding authorized treatment center throughput alongside partner Vertex Pharmaceuticals. — bullish pressure on XBI. — bullish pressure on XBI.
Commercialization of gene-editing therapies is demonstrating accelerated inflection in real-world patient starts. CRISPR Therapeutics disclosed that quarterly Casgevy revenue climbed 78% sequentially to $76 million. The commercial ramp was supported by the FDA expanding Casgevy's approved indication to include pediatric patients aged 2 years and older, significantly expanding authorized treatment center throughput alongside partner Vertex Pharmaceuticals. — bullish pressure on XBI.
- SummaryCommercialization of gene-editing therapies is demonstrating accelerated inflection in real-world patient starts. CRISPR Therapeutics disclosed that quarterly Casgevy revenue climbed 78% sequentially to $76 million. The commercial ramp was supported by the FDA expanding Casgevy's approved indication to include pediatric patients aged 2 years and older, significantly expanding authorized treatment center throughput alongside partner Vertex Pharmaceuticals. — bullish pressure on XBI.
- XBIDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- XBI closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- XBI price vs. pre-event level
- XBI volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| XBI | Bullishdisagreed | 159.38 2026-09-09 | -1.61% | -3.26% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-19Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO CongressXBI ZNTL
- 2026-10-19Viking Therapeutics raises $575M via equity and convertible notesXBI
- 2026-10-19Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO CongressXBI
- 2026-10-19Viking Therapeutics raises $575M via equity and convertible notesVKTX XBI
- 2026-10-06Spyre Therapeutics Prices $350 Million Public Equity Offering at $85 Per ShareSYRE XBI
- 2026-10-04Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug TrialGMAB XBI
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17XBI-0.39%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17ADRX XBI-3.04%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.